Mankind Pharma Limited
All news and filings related to Mankind Pharma Limited.
View all news & filings- Medium impact
Mankind Pharma: Members Approve Appointment of Mr. Anish Vanraj Bafna as Independent Director
Mankind Pharma Limited members approved the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The special resolution passed via remote e-voting, which concluded on September 17, 2026. Mr. Bafna's appointment is for five consecutive years starting August 10, 2026.
Read the summary - Low impact
Mankind Pharma receives 'Leader' category ESG rating from Niche99
Mankind Pharma Limited received a 'Leader' category ESG rating of 68.21 from Niche99 ESG Ratings for FY 2025-26. The rating was assigned independently by Niche99 based on public disclosures.
Read the summary - Low impact
Mankind Pharma Subsidiary BSVL Members Approve Voluntary Liquidation
Mankind Pharma Limited's wholly-owned subsidiary, BSVL, received member approval for voluntary liquidation during an EGM on September 7, 2026. This is subject to creditor approval under the Insolvency and Bankruptcy Code.
Read the summary - Low impact
Mankind Pharma Completes Sale of Broadway Hospitality Stake
Mankind Pharma Limited has completed the sale of its 100% stake in Broadway Hospitality Services Private Limited to AKRK Projects LLP and its Partners. The transaction was finalized on August 31, 2026, making Broadway no longer a subsidiary.
Read the summary - Low impact
Mankind Pharma: Independent Director Mr. Bharat Anand Completes Term on Aug 30, 2026
Mr. Bharat Anand has completed his second term as an Independent Director for Mankind Pharma Limited and ceases to be an Independent Director effective August 30, 2026. He has also stepped down from board committees.
Read the summary - Medium impact
Mankind Pharma to liquidate subsidiary BSVL, consolidate business
Mankind Pharma's Board approved the voluntary liquidation of subsidiary BSVL. The business will be consolidated into Mankind Pharma, with Appian Properties receiving cash for its 4% stake based on valuation. This aims to drive operational efficiency and resource utilization.
Read the summary - Medium impact
Mankind Pharma initiates voluntary liquidation of subsidiary BSVL for business consolidation
Mankind Pharma's Board approved the voluntary liquidation of its subsidiary BSVL. The business will be consolidated into Mankind Pharma, with Appian Properties receiving cash for its stake. This aims to improve efficiency and resource utilization.
Read the summary - Medium impact
Mankind Pharma's ESG Rating Improves to 'Strong' Category with 64 Score
Mankind Pharma's ESG rating improved to 64 ('Strong' category) from 57 ('Adequate'). Core ESG rating increased to 71 from 60. CRISIL ESG Ratings provided the independent assessment based on FY2026 disclosures and public information. The details are available on the company's website.
Read the summary - Medium impact
Mankind Pharma inks exclusive in-licensing deal for Insulin Degludec in India
Mankind Pharma Limited has signed an exclusive in-licensing and marketing agreement with China's Chongqing Chenan Biopharmaceutical Co., Ltd. for Insulin Degludec and Insulin Degludec + Aspart Combination in India. This deal strengthens Mankind's diabetes care portfolio and its presence in the injectable diabetes segment.
Read the summary - Low impact
Mankind Pharma Publishes Newspaper Ads for Postal Ballot Notice
Mankind Pharma Limited published newspaper advertisements on August 19, 2026, confirming the dispatch of its Notice of Postal Ballot. This follows an intimation on August 18, 2026, and complies with company law and listing regulations. The notice is also available on the company's website.
Read the summary - Low impact
Mankind Pharma seeks member approval for Anish Bafna's appointment as Independent Director
Mankind Pharma is seeking member approval via postal ballot for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. E-voting will take place from August 19 to September 17, 2026, with results expected by September 21, 2026. Mr. Bafna has over 30 years of experience in the healthcare sector.
Read the summary - Low impact
Mankind Pharma Completes NCD Security Realignment, Releases 28,280 BSVL Shares
Mankind Pharma completed realignment of NCD security cover. 28,280 equity shares of Bharat Serums and Vaccines Limited (BSVL), representing 38.68% stake, were released from pledge on August 17, 2026. Revised security cover is 1.26 times outstanding NCDs.
Read the summary - Low impact
Mankind Pharma Appoints Anish Vanraj Bafna as Additional Non-Executive Independent Director
Mankind Pharma Limited appointed Mr. Anish Vanraj Bafna as Additional Non-Executive Independent Director, effective August 10, 2026. His appointment is for a five-year term, subject to shareholder approval via postal ballot. Mr. Bafna has over 30 years of experience in the healthcare sector.
Read the summary - Medium impact
Mankind Pharma Appoints Anish Vanraj Bafna as Additional Non-Executive Independent Director
Mankind Pharma's Board approved the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director, effective August 10, 2026. The appointment is for a 5-year term, subject to shareholder approval via postal ballot. Mr. Bafna has over 30 years of experience in the healthcare sector.
Read the summary - Low impact
Mankind Pharma to Participate in Multiple Investor Conferences in August 2026
Mankind Pharma Limited will participate in investor conferences in August 2026. Key events include the Emkay Confluence and Equirus Annual India Conference on August 13, and the Motilal Oswal Global Investor Conference on August 17. No UPSI will be disclosed.
Read the summary - Medium impact
Mankind Pharma's 35th AGM: All Resolutions Approved with Requisite Majority
Mankind Pharma's 35th AGM on August 4, 2026, successfully passed all four resolutions. Key approvals included financial statement adoption and director re-appointments for Mr. Rajeev Juneja and Mr. Satish Kumar Sharma. Cost auditor remuneration for FY27 was also ratified.
Read the summary - Low impact
Mankind Pharma Holds 35th AGM on Aug 4, 2026; Discusses FY26 Financials
Mankind Pharma Limited conducted its 35th AGM on August 4, 2026, discussing FY26 financials and approving key resolutions including financial statements and director re-appointments. The meeting was held via video conference, with updates provided by the CEO and CFO.
Read the summary - High impact
Mankind Pharma Q1 FY27 Earnings Call Transcript Released
Mankind Pharma reported Q1 FY27 revenue of ₹4,031 crore, up 13% YoY. EBITDA margin improved to 26.3%. Domestic revenue grew 11% to ₹3,180 crore. International business grew 29% to ₹605 crore. Profit after tax increased 29.1% to ₹574 crore.
Read the summary - Medium impact
Mankind Pharma Q1FY27 Revenue at ₹4,030.59 Cr, Profit at ₹574.09 Cr
Mankind Pharma reported consolidated revenue of ₹4,030.59 crore and profit after tax of ₹574.09 crore for Q1 FY27. Standalone revenue was ₹2,964.05 crore and profit after tax was ₹558.49 crore. The results were approved by the Board on July 30, 2026.
Read the summary - Low impact
Mankind Pharma Q1FY27 Investor Call Audio Recording Available
Mankind Pharma Limited has released the audio recording of its Q1FY27 investor conference call held on July 30, 2026. The recording is available on the company's website.
Read the summary - Medium impact
Mankind Pharma Q1 FY27 Results: Standalone Revenue ₹2,964 Crore, Consolidated Revenue ₹4,030 Crore
Mankind Pharma reported standalone revenue of ₹2,964 crore and consolidated revenue of ₹4,030 crore for the quarter ended June 30, 2026. The company approved issuing a corporate guarantee for its subsidiary BSV and the sale of its stake in Broadway Hospitality Services for ₹49 crore.
Read the summary - High impact
Mankind Pharma Q1FY27 Revenue up 13% to ₹4,031 Cr; PAT grows 29% to ₹574 Cr
Mankind Pharma reported Q1 FY27 consolidated revenue of ₹4,031 Cr, up 12.9% YoY. EBITDA grew 24.7% to ₹1,060 Cr, and PAT increased 29.1% to ₹574 Cr. Domestic revenue rose 10.5% to ₹3,426 Cr, while exports grew 29.0% to ₹605 Cr. An earnings concall is scheduled for July 30, 2026.
Read the summary - High impact
Mankind Pharma Q1 FY27 Revenue Grows 13% to ₹4,031 Crore; EBITDA Up 24.7%
Mankind Pharma reported Q1 FY27 revenue of ₹4,031 Crore, up 13% YoY. EBITDA increased by 24.7% to ₹1,060 Crore, and PAT rose 29.1% to ₹574 Crore. Domestic business grew 11.0%, exports 29%, and consumer healthcare 4%. EBITDA margins improved to 26.3%.
Read the summary - Medium impact
Mankind Pharma Board Approves Financial Results and Corporate Guarantee for Subsidiary
Mankind Pharma reported unaudited standalone revenue of ₹2,964.05 crore and consolidated revenue of ₹4,030.59 crore for Q1 FY27. The board approved a corporate guarantee for subsidiary BSV and investments in subsidiaries. The company also plans to divest its stake in Broadway Hospitality Services for ₹49 crore.
Read the summary - Medium impact
Mankind Pharma Approves Q1 FY27 Standalone & Consolidated Results, Issues Corporate Guarantee
Mankind Pharma reported Q1 FY27 unaudited results with standalone profit after tax at ₹558.49 crore and consolidated profit after tax at ₹574.09 crore. The Board approved issuing a corporate guarantee for its subsidiary, Bharat Serums and Vaccines Limited (BSV). The company also disclosed an investment of ₹50 crore in Mankind Medicare Private Limited and the divestment of its stake in Broadway Hospitality Services Private Limited for ₹49 crore.
Read the summary - Medium impact
Mankind Pharma Completes 100% Stake Sale in Broadway Hospitality for ₹49 Crore
Mankind Pharma Limited completed the sale of its 100% stake in Broadway Hospitality Services Private Limited for a cash consideration of ₹49 Crore on July 27, 2026. The transaction is subject to closing adjustments.
Read the summary - Low impact
Mankind Pharma Invites to Q1FY27 Investor Conference Call on July 30, 2026
Mankind Pharma Limited will host an investor conference call on July 30, 2026, at 06:30 PM IST to discuss Q1FY27 performance. Key management, including the Vice Chairman & MD and CEO, will be present.
Read the summary - Medium impact
Mankind Pharma to Divest Broadway Hospitality for ₹49 Crore, Incorporates Netherlands Subsidiary
Mankind Pharma will divest its entire stake in Broadway Hospitality Services for ₹49 Crore. The company will also incorporate a wholly-owned subsidiary in Netherlands with an investment of up to Euro 5 Million for R&D and business development in niche therapies. The divestment is expected to complete within 90 days.
Read the summary - Medium impact
Mankind Pharma to Divest 100% Stake in Broadway Hospitality for ₹49 Crore; Incorporates Netherlands Subsidiary
Mankind Pharma will divest its 100% stake in Broadway Hospitality for ₹49 Crores. The company will also incorporate a wholly-owned subsidiary in Netherlands with an investment of up to Euro 5 Million (approx. ₹45 Crore) for R&D and business development in niche therapies. The divestment is expected to complete within 90 days.
Read the summary - Medium impact
Mankind Pharma to Divest Broadway Hospitality for ₹49 Cr, Incorporate Netherlands Subsidiary
Mankind Pharma will divest its 100% stake in Broadway Hospitality Services for ₹49 Crore. The company will also establish a wholly-owned subsidiary in the Netherlands with an investment of up to Euro 5 Million for R&D and niche therapy business development. The divestment is expected to complete within 90 days.
Read the summary - Low impact
Mankind Pharma Files SEBI Compliance Certificate for Q1FY27
Mankind Pharma Limited submitted a compliance certificate for the quarter ended June 30, 2026. The Registrar and Share Transfer Agent confirmed no share dematerialisation or rematerialisation requests were received during the period April 1, 2026, to June 30, 2026.
Read the summary - Low impact
Mankind Pharma Announces 35th AGM on August 4, 2026, via Video Conferencing
Mankind Pharma Limited will hold its 35th Annual General Meeting on August 4, 2026, via Video Conferencing. Remote e-voting will be available from August 1 to August 30, 2026. The Annual Report for FY 2025-26 has been distributed. Members are also reminded to claim any unclaimed interim dividends for FY 2025-26.
Read the summary - Low impact
Mankind Pharma Announces 35th AGM on August 4, 2026
Mankind Pharma Limited will hold its 35th Annual General Meeting (AGM) on August 4, 2026, at 3:30 PM IST via Video Conference. The company has published newspaper advertisements and will provide AGM notice and annual reports electronically to registered members. E-voting facilities will be available.
Read the summary - Low impact
Mankind Pharma Schedules 35th AGM for August 4, 2026
Mankind Pharma Limited's 35th Annual General Meeting is scheduled for August 4, 2026. The meeting will be held via video conference. The Annual Report for FY2025-26 will be shared with members soon.
Read the summary - Low impact
Mankind Pharma to Participate in IIFL Invest India Conference on June 23-24, 2026
Mankind Pharma Limited will participate in IIFL's Invest India Conference & Capital Day 2026 in London on June 23-24, 2026. Management will hold one-on-one and group meetings. No unpublished price-sensitive information will be shared.
Read the summary - Low impact
Mankind Pharma Promoters Confirm No Share Encumbrance for FY26
Mankind Pharma's Promoters and Promoter Group confirmed no share encumbrance for the financial year ended March 31, 2026. This disclosure complies with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Read the summary - Medium impact
Mankind Pharma subsidiary acquires remaining 10% stake in Upakarma Ayurveda for ₹75 Lakhs
Mankind Pharma's subsidiary, MLS, acquired the remaining 10% stake in Upakarma Ayurveda for ₹75 Lakhs. This makes Upakarma a step-down wholly owned subsidiary of Mankind Pharma. Upakarma reported a turnover of ₹18.02 Crores for FY26. The acquisition aims to improve operational efficiencies.
Read the summary - Low impact
Mankind Pharma to Participate in Investor Conference Organized by Bank of America on June 1
Mankind Pharma will participate in an investor conference organized by Bank of America on June 1, 2026. The company will also hold investor meetings on June 2, 2026. No unpublished price sensitive information will be disclosed.
Read the summary - Medium impact
Mankind Pharma Q4 FY26 Earnings Call Transcript Released
Mankind Pharma's Q4 FY26 revenue grew 11.8% YoY to ₹3,443 crore, with full-year revenue at ₹14,278 crore, up 17.0%. Adjusted EBITDA margin for Q4 was 27.1%, and for the full year was 25.4%. Domestic revenue grew 13.4% in Q4. The company expects FY27 to be a better year with double-digit growth.
Read the summary - Low impact
Mankind Pharma Notifies Participation in Investor Meetings in Singapore on May 25-26, 2026
Mankind Pharma's management will meet investors in Singapore on May 25 and May 26, 2026. The discussions will be based on the general business outlook and information already in the public domain. No unpublished price-sensitive information will be disclosed. The schedule is subject to change.
Read the summary - Low impact
Mankind Pharma Q4 & FY26 Investor Call Audio Recording Available
Mankind Pharma Limited has released the audio recording for its Q4 and FY26 investor conference call held on May 20, 2026. The recording is available on the company's website.
Read the summary - High impact
Mankind Pharma Q4 FY26 Results: Revenue at ₹3,442.93 Cr, Profit at ₹559.42 Cr
Mankind Pharma reported Q4 FY26 consolidated revenue of ₹3,442.93 crore and profit of ₹559.42 crore. For FY26, consolidated revenue was ₹14,277.64 crore and profit was ₹1,938.10 crore. Standalone Q4 revenue was ₹2,581.82 crore with profit at ₹713.61 crore. FY26 standalone revenue was ₹10,421.18 crore and profit was ₹2,037.56 crore.
Read the summary - High impact
Mankind Pharma Q4 & FY26 Results: Revenue Up 11.8% YoY to ₹3,443 Cr, Adj. EBITDA Margins at 27.1%
Mankind Pharma reported Q4 FY26 revenue of ₹3,443 crore, up 11.8% YoY, with adjusted EBITDA margins at 27.1%. For FY26, revenue reached ₹14,278 crore, a 17.0% increase. Domestic business grew 14.9%, exports 34.5%. The company maintained its #1 prescription rank.
Read the summary - Medium impact
Mankind Pharma Board Approves FY26 Results, Reappoints Director, Approves Subsidiary Investment
Mankind Pharma reported audited standalone and consolidated results for the year ended March 31, 2026. The Board approved the re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director and approved an investment of up to ₹500 Crores in Mankind Medicare Private Limited. Mr. Pramod Gokhale resigned as Global CIO.
Read the summary - Medium impact
Mankind Pharma Board Approves FY26 Results, Reappoints Whole-Time Director
Mankind Pharma's Board approved FY26 audited financial results. The company will re-appoint Mr. Satish Kumar Sharma as Whole-Time Director for 5 years from Sept 23, 2026. An additional investment of up to ₹500 Crores in a subsidiary was approved. Key executives will forgo their commission for FY25-26.
Read the summary - High impact
Mankind Pharma Approves FY26 Results, Reappoints Director, and Invests ₹500 Cr in Subsidiary
Mankind Pharma approved FY26 results. Reappointed Mr. Satish Kumar Sharma as Whole-Time Director for 5 years from Sept 23, 2026. Approved investment up to ₹500 Cr in Mankind Medicare. Mr. Pramod Gokhale resigned as CIO. Top executives forgo FY26 commission.
Read the summary - Medium impact
Mankind Pharma Board Approves Q4 FY26 Results, Re-appoints Director, Approves Subsidiary Investment
Mankind Pharma reported Q4 FY26 profit after tax of ₹713.61 crore and FY26 profit of ₹2,037.56 crore. The Board approved the financial results, re-appointed Mr. Satish Kumar Sharma as Whole-Time Director for five years from Sept 23, 2026, and approved an investment of up to ₹500 crore in Mankind Medicare Private Limited.
Read the summary - Medium impact
Mankind Pharma Credit Ratings Reaffirmed by ICRA: AA+ (Stable) for Long-term, A1+ for Short-term
Mankind Pharma's credit ratings have been reaffirmed by ICRA. Long-term fund-based limits of ₹1,250 crore rated [ICRA]AA+ (Stable)/[ICRA]A1+. Non-convertible Debentures worth ₹5,000 crore rated [ICRA]AA+ (Stable). Commercial Paper of ₹600 crore assigned [ICRA]A1+.
Read the summary - Low impact
Mankind Pharma Schedules Q4FY26 & FY26 Investor Conference Call for May 20, 2026
Mankind Pharma Limited will host an Investor Conference Call on May 20, 2026, at 12:00 PM IST to discuss Q4FY26 and FY26 business performance and results. Senior management, including the MD and CFO, will be present.
Read the summary - Medium impact
Mankind Pharma Assigned CARE AA+ Stable Rating for Long-term Facilities
Mankind Pharma Limited's ₹1,000 crore long-term and short-term bank facilities have been assigned a credit rating of CARE AA+ Stable and CARE A1+ respectively by CARE Ratings Limited. This rating action was taken at the company's request.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio